IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus

Arthritis and Rheumatism

Volumn 64, Issue 10, 2012, Pages 3383-3387

  Cherian, Tharian S ^a   Kariuki, Silvia N ^a   Franek, Beverly S ^a   Buyon, Jill P ^b   Clancy, Robert M ^b   Niewold, Timothy B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 5; RO ANTIBODY; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, HUMAN;

ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HAPLOTYPE; HUMAN; LUPUS VULGARIS; MAJOR CLINICAL STUDY; NEONATAL LUPUS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ALLELE; DISEASE COURSE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; IMMUNOLOGY; MOTHER;

ALLELES; AUTOIMMUNITY; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTERFERON REGULATORY FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOTHERS; POLYMORPHISM, GENETIC;

EID: 84869044634     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34571     Document Type: Article

References (15)

1. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-66. (Pubitemid 28273312)
2. Rivera TL, Izmirly PM, Birnbaum BK, Byrne P, Brauth JB, Katholi M, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis 2009; 68: 828-35.
3. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007; 56: 3995-4004. (Pubitemid 350262327)
4. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon-activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 1044-53.
5. Niewold TB, Rivera TL, Buyon JP, Crow MK. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/ Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008; 58: 541-6. (Pubitemid 351294888)
6. Niewold TB. Interferon - as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 2011; 31: 887-92.
7. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007; 104: 6758-63. (Pubitemid 47175574)
8. Nordmark G, Kristjansdottir G, Theander E, Eriksson P, Brun JG, Wang C, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes Immun 2009; 10:68-76.
9. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58: 2481-7.
10. Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon - activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 2012; 71: 463-9.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
12. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8. (Pubitemid 34539104)
13. Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, et al. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 2005; 52: 3079-86. (Pubitemid 41447089)
14. Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P, et al. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-mouse models of systemic lupus erythematosus. J Immunol 2010; 184: 796-806.
15. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502. (Pubitemid 47365615)